Genprex, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage gene therapy company with common stock traded on The Nasdaq Capital Market under GNPX. The company’s 8-K reports record material-event disclosures on Reqorsa patent grants and patent-application actions, research agreements, investor presentations, preclinical and clinical data presentations, diabetes gene therapy updates, and Nasdaq listing-compliance matters.
Proxy materials provide governance and compensation disclosures, including director and executive compensation tables, pay-versus-performance information and annual meeting matters. The filing record also ties Genprex’s capital-market status to its common stock listing, minimum stockholders’ equity compliance, and Regulation FD treatment for furnished presentation materials and press-release exhibits.
Genprex reported that its research collaborators will present positive preclinical data on REQORSA (quaratusugene ozeplasmid) for ALK-EML4 positive non-small cell lung cancer at the 2025 AACR-NCI-EORTC conference in Boston. The studies showed that REQORSA increased TUSC2 expression and activated apoptotic pathways across ALK+ cell lines and patient-derived organoids, including models with acquired resistance to the ALK inhibitor alectinib.
In a mouse model, alectinib alone shrank tumors by 60%, while REQORSA alone and the REQORSA–alectinib combination each shrank tumors by 79%. Researchers also observed slower tumor regrowth after combined treatment versus single agents and increased markers of apoptosis (including caspase 3/7 activity). The abstract concludes that these in vitro and in vivo findings support a potential clinical trial of REQORSA in ALK-EML4 positive NSCLC.
Genprex, Inc. (GNPX) effected a one-for-fifty reverse stock split of its common stock, effective at 12:01 a.m. on October 21, 2025. The action consolidates every 50 pre-split shares into 1 share.
After giving effect to the reverse split, the company reports 1,004,326 shares outstanding as of October 21, 2025, prior to any rounding of fractional shares. The filing lists no other corporate changes or transactions related to this event.
Genprex received a Nasdaq Hearings Panel exception to regain compliance with the $1.00 Minimum Bid Price and minimum stockholders’ equity listing standards through October 31, 2025, with Panel discretion to extend to February 9, 2026. The Panel may reconsider the exception, and no further extension is assured.
To support compliance, the Board approved a 1-for-50 reverse stock split effective at 12:01 a.m. ET on October 21, 2025. Trading will begin on a split-adjusted basis that day under ticker GNPX; fractional shares will be rounded up to the next whole share. Par value and authorized shares are unchanged, and outstanding options and warrants will be adjusted per their terms.
Clinical updates: Acclaim-1 (NSCLC) Phase 2a targets ~33 patients with an interim analysis after the first 19; enrollment of those 19 is expected in the first half of 2026 with interim analysis in the second half of 2026 (FDA Fast Track). Acclaim-3 (ES‑SCLC) Phase 2 plans ~50 patients across ~10–15 U.S. sites, with a futility look after the 25th patient reaches 18 weeks; the same first‑half/second‑half 2026 timing is expected (FDA Fast Track and Orphan Drug).
Genprex, Inc. reports that Nasdaq has notified the company it is not in compliance with key listing standards, creating a risk of delisting from the Nasdaq Capital Market. Nasdaq’s Listing Qualifications Staff cited stockholders’ equity of $1,391,195 as of June 30, 2025, which is below the required $2.5 million minimum, and noted the company also does not meet alternative market value or net income standards.
The notice follows an earlier determination to delist Genprex for failing to meet the $1.00 per share minimum bid price requirement within a 180-day grace period and not qualifying for an additional extension due to not meeting Nasdaq’s $5,000,000 initial listing equity threshold. Genprex has requested a hearing before a Nasdaq Hearings Panel, which temporarily stays suspension or delisting while it presents a plan to regain compliance, but the company cautions there is no assurance the panel will grant continued listing.
Genprex, Inc. reported new patent progress for its lead gene therapy, REQORSA (quaratusugene ozeplasmid), in combination with checkpoint inhibitor drugs. The U.S. Patent and Trademark Office issued a notice of allowance for a patent covering REQORSA with PD-L1 antibodies such as Tecentriq, and the European Patent Office issued a notice of allowance for a patent covering REQORSA with PD-1 antibodies. Both patents will expire in 2037 at the earliest.
The company already holds patents for REQORSA with PD-L1 antibodies in Korea and for REQORSA with PD-1 antibodies in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Korea and Singapore, and is pursuing additional applications in Europe, Canada, Brazil, China and Israel that could apply to its Acclaim-3 trial. Acclaim-3 is a Phase 1/2 study of REQORSA plus Genentech’s Tecentriq as maintenance therapy for extensive stage small cell lung cancer, and this trial has received FDA Fast Track and Orphan Drug designations.
Genprex, Inc. reported results of its 2025 annual stockholder meeting. Stockholders approved an amended and restated 2018 Equity Incentive Plan, adding authorization for an additional 6,500,000 shares of common stock, extending the plan term to June 30, 2035, and removing outdated tax-driven performance compensation provisions. They re-elected Class II director William R. Wilson, Jr. and ratified WithumSmith+Brown, PC as auditor for the year ending December 31, 2025.
Investors gave advisory approval to named executive officer pay and formally approved the amended equity plan. They also approved, under Nasdaq Listing Rule 5635(d), a potential issuance of more than 20% of outstanding common stock under the company’s purchase agreement with Lincoln Park Capital Fund, LLC. In addition, stockholders authorized a reverse stock split of issued common shares at a ratio between 1-for-10 and 1-for-50, which the board may implement at its discretion any time before December 31, 2026.